SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of matters to a vote of Security Holders.

On September27, 2017, SciClone Pharmaceuticals, Inc., a Delaware corporation (the “Company”), held a special meeting (the “Special Meeting”) of the stockholders of the Company (the “Stockholders”) in connection with the transaction contemplated by that certain Agreement and Plan of Merger, dated June7, 2017 (the “Merger Agreement”), between the Company, Silver Biotech Investment Limited, a company organized under the laws of the Cayman Islands (“Holdco”), and Silver Delaware Investment Limited, a Delaware corporation and wholly owned subsidiary of Holdco (“Merger Sub”), under which Merger Sub will be merged with and into the Company (the “Merger”), with the Company continuing after the Merger as the surviving corporation and subsidiary of Holdco.

At the Special Meeting, shares constituting a quorum to conduct business were present in person or by proxy, and all proposals considered and voted on by the Stockholders at the Special Meeting were approved. The proposals are described in detail in the Company’s definitive proxy statement filed on August18, 2017 with the Securities and Exchange Commission (the “SEC”) and the supplemental disclosures filed with the SEC in the Company’s Report on Schedule 14A on September15, 2017.

The following summarizes each of the proposals and the voting results thereon:

Proposal 1 – Approval of the Merger Agreement and the Merger

At the Special Meeting, the Stockholders voted on the proposal to approve and adopt the Merger Agreement and approve the Merger and other transactions contemplated by the Merger Agreement.

Proposal 2 – Adjournment of the Special Meeting

At the Special Meeting, the Stockholders voted on the proposal to adjourn the special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to approve and adopt the Merger Agreement and approve the Merger at the time of the Special Meeting.

Proposal 3 – Advisory Vote to Approve Merger-Related Compensation

At the Special Meeting, the Stockholders voted on the non-binding, advisory proposal to approve certain compensation payable or that may become payable to the Company’s named executive officers in connection with the Merger.

About SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in approximately 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, the Company markets approximately seven partnered and in-licensed products in China. The Company’s development portfolio includes Angiomax, Neucardin, Loramyc, Cleviprex, RapidFilm, VIBATIV and SGX942. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).